Target therapy of ovarian carcinoma by monoclonal antibodies bearing chemical drugs entrapped in liposomes.
Monoclonal antibody COC166-9 against ovarian carcinoma was conjugated with adriamycin or cisplatinum entraped in liposomes as immunochemical liposomes MLA and MLP respectively. MLA was shown to have the highest effect than adriamycin or other groups on SKOV3 (ovarian cancer cell line) growth inhibition. MLA was also used in target therapy on nude mice bearing human ovarian carcinoma by xenograft of SKOV3 cells. The observations of tumor volumes revealed that this target therapy other than the controls presents a significantly better result which gives a hopeful clue to ovarian carcinoma treatment.
Qian
H N
HN
Gynecologic Oncology Research Laboratory, People's Hospital, Beijing Medical University.
Li
W J
WJ
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage*; D003536:Cystadenocarcinoma / Q000473:pathology / Q000628:therapy*; D004317:Doxorubicin / Q000008:administration & dosage*; D004337:Drug Carriers; D005260:Female; D000922:Immunotoxins / Q000627:therapeutic use*; D008081:Liposomes; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy*; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000911:Antibodies, Monoclonal; D004337:Drug Carriers; D000922:Immunotoxins; D008081:Liposomes; D004317:Doxorubicin; D002945:Cisplatin